Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
Stopped Due to Sponsor's decision, only 12 patients were randomized \& completed study.
Conditions
Interventions
- BIOLOGICAL: Biological/Vaccine: BC-819
Sponsor
Anchiano Therapeutics Israel Ltd.